DECOY THERAPEUTICS INC · Data as of 2026-09-08
H1 2027
We anticipate higher research and development expense in upcoming quarters as the Company continues on its intended path to file an IND application with the FDA or the European equivalent CTA during the first half of 2027.Source filing
H1 2027
The Company plans to file an Investigational New Drug ( "IND") application with the United States Food and Drug Administration ( "FDA") or the European equivalent clinical trial application ("CTA") during the first half of 2027 and to continue to pursue non-dilutive funding and a development partner for clinical development.Source filing